NASDAQ:BIOS - BioScrip Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.51 -0.02 (-0.79 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$2.53
Today's Range$2.49 - $2.55
52-Week Range$1.69 - $3.39
Volume366,446 shs
Average Volume787,079 shs
Market Capitalization$313.48 million
P/E Ratio-5.70
Dividend YieldN/A
Beta0.08

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Debt-to-Equity Ratio-4.79
Current Ratio1.70
Quick Ratio1.30

Price-To-Earnings

Trailing P/E Ratio-5.70
Forward P/E Ratio-8.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$817.19 million
Price / Sales0.39
Cash FlowN/A
Price / CashN/A
Book Value($0.78) per share
Price / Book-3.22

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-9.23%
Return on EquityN/A
Return on Assets-8.77%

Miscellaneous

Employees2,154
Outstanding Shares127,950,000

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) posted its quarterly earnings results on Thursday, May, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company had revenue of $168.60 million for the quarter, compared to analysts' expectations of $164.72 million. The firm's quarterly revenue was down 22.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.18) earnings per share. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 brokers have issued 1-year target prices for BioScrip's stock. Their forecasts range from $3.25 to $4.00. On average, they expect BioScrip's stock price to reach $3.5625 in the next year. View Analyst Ratings for BioScrip.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 51)
  • Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
  • Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)

Has BioScrip been receiving favorable news coverage?

Media stories about BIOS stock have been trending somewhat negative this week, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioScrip earned a daily sentiment score of -0.01 on Accern's scale. They also gave news headlines about the company an impact score of 47.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are BioScrip's major shareholders?

BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Venor Capital Management LP (11.45%), Gabelli Funds LLC (8.00%), BlackRock Inc. (5.18%), Diamond Hill Capital Management Inc. (3.16%), Wynnefield Capital Inc. (2.37%) and Millennium Management LLC (1.90%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Which institutional investors are selling BioScrip stock?

BIOS stock was sold by a variety of institutional investors in the last quarter, including Alta Fundamental Advisers LLC, California Public Employees Retirement System, Gabelli Funds LLC, UBS Group AG, Teton Advisors Inc., Wells Fargo & Company MN, Wynnefield Capital Inc. and Royal Bank of Canada. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

Which institutional investors are buying BioScrip stock?

BIOS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Venor Capital Management LP, Millrace Asset Group Inc., Cambridge Investment Research Advisors Inc., GSA Capital Partners LLP, Diamond Hill Capital Management Inc. and Schwab Charles Investment Management Inc.. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $2.51.

How big of a company is BioScrip?

BioScrip has a market capitalization of $313.48 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioScrip (NASDAQ:BIOS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for BioScrip in the last 12 months. Their average twelve-month price target is $3.5625, suggesting that the stock has a possible upside of 41.93%. The high price target for BIOS is $4.00 and the low price target for BIOS is $3.25. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.5625$3.5625$3.8333$3.75
Price Target Upside: 41.93% upside37.28% upside44.65% upside81.16% upside

BioScrip (NASDAQ:BIOS) Consensus Price Target History

Price Target History for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018SunTrust BanksReiterated RatingBuy$3.25MediumView Rating Details
3/8/2018Craig HallumReiterated RatingBuy$3.50MediumView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$3.00 ➝ $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

BioScrip (NASDAQ:BIOS) Earnings History and Estimates Chart

Earnings by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.10)($0.06)($0.08)
Q2 20182($0.07)($0.05)($0.06)
Q3 20182($0.06)($0.03)($0.05)
Q4 20182($0.01)$0.00($0.01)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.03)($0.03)($0.03)
Q3 20191($0.02)($0.02)($0.02)

BioScrip (NASDAQ BIOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.10)N/AView Earnings Details
5/10/2018Q1 2018($0.11)($0.12)$164.72 million$168.60 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.08)($0.15)$171.35 million$182.50 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.10)($0.12)$202.91 million$198.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
11/6/2013Q3 2013$0.01$0.02$205.09 million$208.88 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
11/2/2010Q3 2010$0.09$0.05ViewN/AView Earnings Details
7/30/2010Q2 2010$0.09$0.07ViewN/AView Earnings Details
4/30/2010Q1 2010$0.07($0.01)ViewN/AView Earnings Details
2/26/2010Q4 2009$0.10$0.03ViewN/AView Earnings Details
10/30/2009Q3 2009$0.10$0.14ViewN/AView Earnings Details
7/30/2009Q2 2009$0.06$0.11ViewN/AView Earnings Details
4/30/2009Q1 2009$0.04$0.08ViewN/AView Earnings Details
3/3/2009Q4 2008$0.05$0.09ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.06ViewN/AView Earnings Details
7/31/2008Q2 2008$0.03$0.04ViewN/AView Earnings Details
5/2/2008Q1 2008$0.05($0.01)ViewN/AView Earnings Details
3/4/2008Q4 2007$0.04$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioScrip (NASDAQ:BIOS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioScrip (NASDAQ BIOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 85.47%
Insider Trading History for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2017Daniel E GreenleafCEOBuy15,000$2.03$30,450.0031,000View SEC Filing  
11/9/2017Stephen DeitschCFOBuy10,000$2.03$20,300.0010,000View SEC Filing  
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00129,669View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.0022,628View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.0016,000View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.0084,000View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.0042,500View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.0030,000View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.0015,000View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.002,580View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.0071,360View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.785,088View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioScrip (NASDAQ BIOS) News Headlines

Source:
DateHeadline
Head to Head Survey: LHC Group (LHCG) and BioScrip (BIOS)Head to Head Survey: LHC Group (LHCG) and BioScrip (BIOS)
www.americanbankingnews.com - May 18 at 3:22 PM
BioScrip to Participate in Upcoming Investor ConferencesBioScrip to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 16 at 5:50 PM
BioScrips Core Business Strong Despite Reimbursement IssuesBioScrip's Core Business Strong Despite Reimbursement Issues
www.zacks.com - May 15 at 5:53 PM
BioScrip (BIOS) Upgraded at Zacks Investment ResearchBioScrip (BIOS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 15 at 1:08 PM
Financial Survey: BioScrip (BIOS) vs. Chemed (CHE)Financial Survey: BioScrip (BIOS) vs. Chemed (CHE)
www.americanbankingnews.com - May 13 at 5:17 PM
Financial Survey: BioScrip (BIOS) and LHC Group (LHCG)Financial Survey: BioScrip (BIOS) and LHC Group (LHCG)
www.americanbankingnews.com - May 12 at 3:43 PM
Chemed (CHE) versus BioScrip (BIOS) Critical SurveyChemed (CHE) versus BioScrip (BIOS) Critical Survey
www.americanbankingnews.com - May 11 at 3:06 PM
Edited Transcript of BIOS earnings conference call or presentation 10-May-18 1:00pm GMTEdited Transcript of BIOS earnings conference call or presentation 10-May-18 1:00pm GMT
finance.yahoo.com - May 11 at 8:15 AM
BioScrip (BIOS) Releases  Earnings Results, Misses Estimates By $0.01 EPSBioScrip (BIOS) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 6:12 PM
BioScrip: 1Q Earnings SnapshotBioScrip: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 6:04 PM
BioScrip Reports First Quarter 2018 Financial ResultsBioScrip Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 6:04 PM
$166.99 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter$166.99 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter
www.americanbankingnews.com - May 8 at 2:26 AM
 Brokerages Expect BioScrip, Inc. (BIOS) Will Post Earnings of -$0.11 Per Share Brokerages Expect BioScrip, Inc. (BIOS) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - May 6 at 6:28 PM
LHC Group (LHCG) versus BioScrip (BIOS) Critical AnalysisLHC Group (LHCG) versus BioScrip (BIOS) Critical Analysis
www.americanbankingnews.com - May 6 at 10:05 AM
LHC Group (LHCG) & BioScrip (BIOS) Financial ContrastLHC Group (LHCG) & BioScrip (BIOS) Financial Contrast
www.americanbankingnews.com - May 3 at 3:46 PM
BioScrip (BIOS) to Release Quarterly Earnings on ThursdayBioScrip (BIOS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 3:32 AM
BioScrip, Inc. (BIOS) Receives Average Recommendation of "Hold" from AnalystsBioScrip, Inc. (BIOS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 3 at 3:24 AM
Head-To-Head Review: Chemed (CHE) versus BioScrip (BIOS)Head-To-Head Review: Chemed (CHE) versus BioScrip (BIOS)
www.americanbankingnews.com - April 26 at 7:20 PM
BioScrip Schedules Release of First Quarter 2018 Financial Results and Conference CallBioScrip Schedules Release of First Quarter 2018 Financial Results and Conference Call
finance.yahoo.com - April 26 at 5:20 PM
Financial Contrast: BioScrip (BIOS) versus Chemed (CHE)Financial Contrast: BioScrip (BIOS) versus Chemed (CHE)
www.americanbankingnews.com - April 25 at 7:30 PM
BioScrip (BIOS) & Addus HomeCare (ADUS) Head-To-Head ContrastBioScrip (BIOS) & Addus HomeCare (ADUS) Head-To-Head Contrast
www.americanbankingnews.com - April 25 at 10:00 AM
BioScrip (BIOS) to Release Quarterly Earnings on WednesdayBioScrip (BIOS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:32 AM
Comparing Chemed (CHE) & BioScrip (BIOS)Comparing Chemed (CHE) & BioScrip (BIOS)
www.americanbankingnews.com - April 23 at 9:30 AM
BioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $170.23 MillionBioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $170.23 Million
www.americanbankingnews.com - April 21 at 2:34 AM
Head to Head Survey: BioScrip (BIOS) & Amedisys Home Health and Hospice Care (AMED)Head to Head Survey: BioScrip (BIOS) & Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 20 at 9:22 PM
-$0.11 Earnings Per Share Expected for BioScrip, Inc. (BIOS) This Quarter-$0.11 Earnings Per Share Expected for BioScrip, Inc. (BIOS) This Quarter
www.americanbankingnews.com - April 19 at 5:20 PM
Analyzing Chemed (CHE) & BioScrip (BIOS)Analyzing Chemed (CHE) & BioScrip (BIOS)
www.americanbankingnews.com - April 19 at 1:23 AM
Pre-Market Technical Scan on Healthcare Equities -- Heron Therapeutics, Immune Pharma, Johnson & Johnson, and ...Pre-Market Technical Scan on Healthcare Equities -- Heron Therapeutics, Immune Pharma, Johnson & Johnson, and ...
www.prnewswire.com - April 18 at 8:11 AM
BioScrip (BIOS) Rating Lowered to Buy at BidaskClubBioScrip (BIOS) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
BioScrip (BIOS) Cut to Sell at ValuEngineBioScrip (BIOS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM
BioScrip Inc’s (NASDAQ:BIOS) Earnings Dropped -62.14%, Did Its Industry Show Weakness Too?BioScrip Inc’s (NASDAQ:BIOS) Earnings Dropped -62.14%, Did Its Industry Show Weakness Too?
finance.yahoo.com - April 11 at 8:23 AM
BioScrip (BIOS) Lifted to "Buy" at SunTrust BanksBioScrip (BIOS) Lifted to "Buy" at SunTrust Banks
www.americanbankingnews.com - April 11 at 12:11 AM
BioScrip (BIOS) Raised to Hold at ValuEngineBioScrip (BIOS) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 5:02 PM
Reviewing BioScrip (BIOS) and Civitas Solutions (CIVI)Reviewing BioScrip (BIOS) and Civitas Solutions (CIVI)
www.americanbankingnews.com - April 9 at 11:19 PM
Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report?Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report?
finance.yahoo.com - April 9 at 8:13 AM
Analyzing BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)Analyzing BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 8 at 5:06 PM
BioScrip Inc (BIOS) Given Average Rating of "Hold" by AnalystsBioScrip Inc (BIOS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 8 at 3:36 AM
Blog Exposure - Addus Homecare Completes Acquisition of Arcadia Home Care & Staffing for $18.5 MillionBlog Exposure - Addus Homecare Completes Acquisition of Arcadia Home Care & Staffing for $18.5 Million
finance.yahoo.com - April 4 at 8:14 AM
BioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $170.23 MillionBioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $170.23 Million
www.americanbankingnews.com - April 4 at 2:30 AM
 Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.11 Per Share Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 2 at 7:12 PM
BioScrip (BIOS) Upgraded by ValuEngine to "Sell"BioScrip (BIOS) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 1 at 12:08 AM
BioScrip (BIOS) Upgraded to "Buy" by BidaskClubBioScrip (BIOS) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
BioScrip Timely Files Annual Form 10-K, Concludes Accounting Review and Provides Update on Immaterial Financial Statement CorrectionsBioScrip Timely Files Annual Form 10-K, Concludes Accounting Review and Provides Update on Immaterial Financial Statement Corrections
finance.yahoo.com - March 26 at 8:16 AM
Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM
New Research Coverage Highlights Real Goods Solar, LivePerson, Manhattan Associates, Natus Medical, BioScrip, and FBL Financial Group -- Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Real Goods Solar, LivePerson, Manhattan Associates, Natus Medical, BioScrip, and FBL Financial Group -- Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - March 21 at 8:41 AM
What does BioScrip Inc’s (NASDAQ:BIOS) Balance Sheet Tell Us About Its Future?What does BioScrip Inc’s (NASDAQ:BIOS) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - March 19 at 5:22 PM
BioScrips Dull 2017 Earnings a Woe, Core Business RobustBioScrip's Dull 2017 Earnings a Woe, Core Business Robust
finance.yahoo.com - March 16 at 6:34 PM
Zacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPSZacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPS
www.americanbankingnews.com - March 16 at 3:52 PM
BioScrip Provides Update on Annual Form 10-K Filing Status ... - Business Wire (press release)BioScrip Provides Update on Annual Form 10-K Filing Status ... - Business Wire (press release)
www.businesswire.com - March 16 at 8:13 AM
Why BioScrip (BIOS) Could Be Positioned for a Slump - NasdaqWhy BioScrip (BIOS) Could Be Positioned for a Slump - Nasdaq
www.nasdaq.com - March 15 at 8:10 AM

SEC Filings

BioScrip (NASDAQ:BIOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioScrip (NASDAQ:BIOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioScrip (NASDAQ BIOS) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.